Capital Advisors Ltd’s Faeth Therapeutics FTH Stock Holding History

Capital Advisors Ltd’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5	Closed	–	–	1496
2022 Q2	$0	Buy	+5	New	+$187	﹤0.01%	1300

Other funds holding FTH

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Advisors Ltd's FTH Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Faeth Therapeutics (FTH) in Q3 2022, closing a stake of 5 shares.

Capital Advisors Ltd first reported a position in FTH in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 30 funds tracked by Wall St. Rank hold FTH as of Q3 2022.

Capital Advisors Ltd reported no remaining Faeth Therapeutics position as of Q3 2022 after selling out during the quarter.
Capital Advisors Ltd sold 5 Faeth Therapeutics shares in Q3 2022.
Capital Advisors Ltd first reported a position in Faeth Therapeutics in Q2 2022 and held it in 1 quarter.
Capital Advisors Ltd's Faeth Therapeutics position peaked at $0 in Q2 2022.
30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.